SUNDAY trial Primary Objective: To compare the overall survival at five years between subjects treated with SMT or SMT + subacute TEVAR. For more —> sundaytrial.dk

Nice to see this update on the early days from the SUNDAY trial: 👉🏼 ejves.com/article/S1078-… #Sundaytrial #TEVAR #aortaed #vascularsurgery Jacob Budtz-Lilly Tim Resch Kevin Mani

Excellent upcoming program at the jointed #IRAD / GenTAC Alliance meeting in Tromsø, with up-to-date talks on #aorticdissection. Be sure to catch Jacob Budtz-Lilly presenting the SUNDAY trial - over 50 patients already included! #aortaed #SUNDAYtrial TheMarfanFoundation

#IRAD / GenTAC Alliance meeting kick-off in Tromsø today. PI Jacob Budtz-Lilly will talk tomorrow about SUNDAY trial at the session on clinical trials for #TBAD stent graft therapy. Stay tuned… #aortaed #aorticdissection #dissection #aorta TheMarfanFoundation

Be sure to catch Tim Resch at the IADS next week giving a talk on SUNDAY trial at the evidence for #TBAD intervention session #aortaed #aorticdissection

So proud of the work of Jacob Budtz-Lilly leading the SUNDAY trial! We need patients

The future holds exciting knowledge … #SUNDAYtrial #IMPORVE-AD #aortaed #TBAD #aorticdissection Firas F Mussa فراس ف موسى Jacob Budtz-Lilly

Pleasure to present status on #SUNDAYtrial in beautiful Tromsø. Grateful to be part of this great community of leading clinicians thriving to improve care for #TBAD Jacob Budtz-Lilly Kim Eagle Eric E. Roselli GenTAC Alliance TheMarfanFoundation #aortaed #aorticdissection #thinkaorta

Pleasure to attend #TromsoAorta24 and give an update on one of these 3 ongoing RCTs for #TBAD Great meeting, thanks to the organizers. The future provides exciting knowledge .. #SUNDAYTrial #aortaed #aorticdissection Jacob Budtz-Lilly GenTAC Alliance TheMarfanFoundation

For more on the initiation on SUNDAY trial see the latest EJVES issue👇🏼 Jacob Budtz-Lilly Kevin Mani Tim Resch #aortaed #TBAD #aorticdissection

The MDT must be the “new normal” for dissection management, Tara Mastracci (Tara Mastracci) of Barts Health tells the IADS audience #aortaed #aorticdissection

“The importance of raising awareness can’t be underestimated…” SUNDAY trial supports this, by improving knowledge through research …

Firas Mussa (Firas F Mussa فراس ف موسى) encourages the IADS audience to adopt a “centrist” position when it comes to treatment options and get involved in the EARNEST, SUNDAY and IMPROVE-AD trials in the interest of producing much-needed data #aortaed #aorticdissection

Medical management or #TEVAR in chronic uncomplicated Type B #AorticDissection. Which is best? We don't know, so we have 3 global clinical trials: IMPROVE-AD (US); SUNDAY (Scandinavia) & EARNEST (UK). It will be interesting to see how they fare. IADS Firas F Mussa فراس ف موسى #AortaEd

Firas Mussa pointing out the 3 ongoing RCTs: #SUNDAYtrial, IMPROVE-AD and EARNEST - all on a quest to secure best #TBAD treatment. Thanks to the IADS for hosting this incredible meeting The future holds exciting knowledge Firas F Mussa فراس ف موسى Colin Bicknell Jacob Budtz-Lilly #aortaed

Good to get an update on the progress of the SUNDAY trial from Tim Resch and of the Earnest trial from Colin Bicknell at the Interdisciplinary Aortic Dissection Symposium - a step closer to having good quality data to guide TBAD management . Kevin Mani Tara Mastracci Bijan Modarai